FilingSEC EDGAR8-K
Fate Therapeutics Enters New ATM Agreement with Leerink and Terminates Jefferies Agreement
· SEC accepted
StageCompleted
Filing content
The company entered into a new $100 million at-the-market offering program with Leerink Partners and terminated its existing sales agreement with Jefferies LLC.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…